#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0542] In one embodiment, one or more adiponectin isoforms or glycoisoforms or adiponectin agonist polypeptides is prepared by recombinant methods.
1-1	0-1	[	_	_	
1-2	1-5	0542	_	_	
1-3	5-6	]	_	_	
1-4	7-9	In	_	_	
1-5	10-13	one	_	_	
1-6	14-24	embodiment	_	_	
1-7	24-25	,	_	_	
1-8	26-29	one	_	_	
1-9	30-32	or	_	_	
1-10	33-37	more	_	_	
1-11	38-49	adiponectin	_	_	
1-12	50-58	isoforms	_	_	
1-13	59-61	or	_	_	
1-14	62-75	glycoisoforms	_	_	
1-15	76-78	or	_	_	
1-16	79-90	adiponectin	_	_	
1-17	91-98	agonist	_	_	
1-18	99-111	polypeptides	_	_	
1-19	112-114	is	_	_	
1-20	115-123	prepared	_	_	
1-21	124-126	by	_	_	
1-22	127-138	recombinant	_	_	
1-23	139-146	methods	_	_	
1-24	146-147	.	_	_	

#Text=Adiponectin or adiponectin agonist polypeptides may be produced recombinantly by inserting a polynucleotide (usually DNA) sequence that encodes the protein into an expression vector and expressing the peptide in an appropriate host.
2-1	148-159	Adiponectin	_	_	
2-2	160-162	or	_	_	
2-3	163-174	adiponectin	_	_	
2-4	175-182	agonist	_	_	
2-5	183-195	polypeptides	_	_	
2-6	196-199	may	_	_	
2-7	200-202	be	_	_	
2-8	203-211	produced	_	_	
2-9	212-225	recombinantly	_	_	
2-10	226-228	by	_	_	
2-11	229-238	inserting	_	_	
2-12	239-240	a	_	_	
2-13	241-255	polynucleotide	_	_	
2-14	256-257	(	_	_	
2-15	257-264	usually	_	_	
2-16	265-268	DNA	_	_	
2-17	268-269	)	_	_	
2-18	270-278	sequence	_	_	
2-19	279-283	that	_	_	
2-20	284-291	encodes	_	_	
2-21	292-295	the	_	_	
2-22	296-303	protein	_	_	
2-23	304-308	into	_	_	
2-24	309-311	an	_	_	
2-25	312-322	expression	_	_	
2-26	323-329	vector	_	_	
2-27	330-333	and	_	_	
2-28	334-344	expressing	_	_	
2-29	345-348	the	_	_	
2-30	349-356	peptide	_	_	
2-31	357-359	in	_	_	
2-32	360-362	an	_	_	
2-33	363-374	appropriate	_	_	
2-34	375-379	host	_	_	
2-35	379-380	.	_	_	

#Text=A polynucleotide encoding the desired polypeptide, whether in fused or mature form, and whether or not containing a signal sequence to permit secretion, may be ligated into expression vectors suitable for any convenient host.
3-1	381-382	A	_	_	
3-2	383-397	polynucleotide	_	_	
3-3	398-406	encoding	_	_	
3-4	407-410	the	_	_	
3-5	411-418	desired	_	_	
3-6	419-430	polypeptide	_	_	
3-7	430-431	,	_	_	
3-8	432-439	whether	_	_	
3-9	440-442	in	_	_	
3-10	443-448	fused	_	_	
3-11	449-451	or	_	_	
3-12	452-458	mature	_	_	
3-13	459-463	form	_	_	
3-14	463-464	,	_	_	
3-15	465-468	and	_	_	
3-16	469-476	whether	_	_	
3-17	477-479	or	_	_	
3-18	480-483	not	_	_	
3-19	484-494	containing	_	_	
3-20	495-496	a	_	_	
3-21	497-503	signal	_	_	
3-22	504-512	sequence	_	_	
3-23	513-515	to	_	_	
3-24	516-522	permit	_	_	
3-25	523-532	secretion	_	_	
3-26	532-533	,	_	_	
3-27	534-537	may	_	_	
3-28	538-540	be	_	_	
3-29	541-548	ligated	_	_	
3-30	549-553	into	_	_	
3-31	554-564	expression	_	_	
3-32	565-572	vectors	_	_	
3-33	573-581	suitable	_	_	
3-34	582-585	for	_	_	
3-35	586-589	any	_	_	
3-36	590-600	convenient	_	_	
3-37	601-605	host	_	_	
3-38	605-606	.	_	_	

#Text=Any of a variety of expression vectors known to those of ordinary skill in the art may be employed, although eukaryotic expression systems are recommended because of the ability of eukaryotic cells to perform post-translational modifications, such as glycosylation.
4-1	607-610	Any	_	_	
4-2	611-613	of	_	_	
4-3	614-615	a	_	_	
4-4	616-623	variety	_	_	
4-5	624-626	of	_	_	
4-6	627-637	expression	_	_	
4-7	638-645	vectors	_	_	
4-8	646-651	known	_	_	
4-9	652-654	to	_	_	
4-10	655-660	those	_	_	
4-11	661-663	of	_	_	
4-12	664-672	ordinary	_	_	
4-13	673-678	skill	_	_	
4-14	679-681	in	_	_	
4-15	682-685	the	_	_	
4-16	686-689	art	_	_	
4-17	690-693	may	_	_	
4-18	694-696	be	_	_	
4-19	697-705	employed	_	_	
4-20	705-706	,	_	_	
4-21	707-715	although	_	_	
4-22	716-726	eukaryotic	_	_	
4-23	727-737	expression	_	_	
4-24	738-745	systems	_	_	
4-25	746-749	are	_	_	
4-26	750-761	recommended	_	_	
4-27	762-769	because	_	_	
4-28	770-772	of	_	_	
4-29	773-776	the	_	_	
4-30	777-784	ability	_	_	
4-31	785-787	of	_	_	
4-32	788-798	eukaryotic	_	_	
4-33	799-804	cells	_	_	
4-34	805-807	to	_	_	
4-35	808-815	perform	_	_	
4-36	816-834	post-translational	_	_	
4-37	835-848	modifications	_	_	
4-38	848-849	,	_	_	
4-39	850-854	such	_	_	
4-40	855-857	as	_	_	
4-41	858-871	glycosylation	_	_	
4-42	871-872	.	_	_	

#Text=Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule which encodes the recombinant peptides.
5-1	873-883	Expression	_	_	
5-2	884-887	may	_	_	
5-3	888-890	be	_	_	
5-4	891-899	achieved	_	_	
5-5	900-902	in	_	_	
5-6	903-906	any	_	_	
5-7	907-918	appropriate	_	_	
5-8	919-923	host	_	_	
5-9	924-928	cell	_	_	
5-10	929-933	that	_	_	
5-11	934-937	has	_	_	
5-12	938-942	been	_	_	
5-13	943-954	transformed	_	_	
5-14	955-957	or	_	_	
5-15	958-969	transfected	_	_	
5-16	970-974	with	_	_	
5-17	975-977	an	_	_	
5-18	978-988	expression	_	_	
5-19	989-995	vector	_	_	
5-20	996-1006	containing	_	_	
5-21	1007-1008	a	_	_	
5-22	1009-1012	DNA	_	_	
5-23	1013-1021	molecule	_	_	
5-24	1022-1027	which	_	_	
5-25	1028-1035	encodes	_	_	
5-26	1036-1039	the	_	_	
5-27	1040-1051	recombinant	_	_	
5-28	1052-1060	peptides	_	_	
5-29	1060-1061	.	_	_	

#Text=Examples of eukaryotic host cells are known in the art and include yeast, avian, insect, plant, and animal cells such as COS7, HeLa, CHO and other mammalian cells.
6-1	1062-1070	Examples	_	_	
6-2	1071-1073	of	_	_	
6-3	1074-1084	eukaryotic	_	_	
6-4	1085-1089	host	_	_	
6-5	1090-1095	cells	_	_	
6-6	1096-1099	are	_	_	
6-7	1100-1105	known	_	_	
6-8	1106-1108	in	_	_	
6-9	1109-1112	the	_	_	
6-10	1113-1116	art	_	_	
6-11	1117-1120	and	_	_	
6-12	1121-1128	include	_	_	
6-13	1129-1134	yeast	_	_	
6-14	1134-1135	,	_	_	
6-15	1136-1141	avian	_	_	
6-16	1141-1142	,	_	_	
6-17	1143-1149	insect	_	_	
6-18	1149-1150	,	_	_	
6-19	1151-1156	plant	_	_	
6-20	1156-1157	,	_	_	
6-21	1158-1161	and	_	_	
6-22	1162-1168	animal	_	_	
6-23	1169-1174	cells	_	_	
6-24	1175-1179	such	_	_	
6-25	1180-1182	as	_	_	
6-26	1183-1187	COS7	_	_	
6-27	1187-1188	,	_	_	
6-28	1189-1193	HeLa	_	_	
6-29	1193-1194	,	_	_	
6-30	1195-1198	CHO	_	_	
6-31	1199-1202	and	_	_	
6-32	1203-1208	other	_	_	
6-33	1209-1218	mammalian	_	_	
6-34	1219-1224	cells	_	_	
6-35	1224-1225	.	_	_	

#Text=Standard techniques for recombinant production are described for example, in Sambrook supra.
7-1	1226-1234	Standard	_	_	
7-2	1235-1245	techniques	_	_	
7-3	1246-1249	for	_	_	
7-4	1250-1261	recombinant	_	_	
7-5	1262-1272	production	_	_	
7-6	1273-1276	are	_	_	
7-7	1277-1286	described	_	_	
7-8	1287-1290	for	_	_	
7-9	1291-1298	example	_	_	
7-10	1298-1299	,	_	_	
7-11	1300-1302	in	_	_	
7-12	1303-1311	Sambrook	_	_	
7-13	1312-1317	supra	_	_	
7-14	1317-1318	.	_	_	

#Text=Adiponectin or adiponectin agonist polypeptides can be obtained by expression of a recombinant polynucleotide encoding adiponectin or a polypeptide having the sequence of any of those animals (e.g., human, mouse, etc.) described in FIG. 5 or a biologically active fragment or addition thereof, or other variant or agonist thereof in mammalian cells.
#Text=[0543] In another embodiment, adiponectin (including mixtures of isoforms and glycoisoforms) can also be purified from an animal tissue such as, but not limited to, serum or adipocytes.
8-1	1319-1330	Adiponectin	_	_	
8-2	1331-1333	or	_	_	
8-3	1334-1345	adiponectin	_	_	
8-4	1346-1353	agonist	_	_	
8-5	1354-1366	polypeptides	_	_	
8-6	1367-1370	can	_	_	
8-7	1371-1373	be	_	_	
8-8	1374-1382	obtained	_	_	
8-9	1383-1385	by	_	_	
8-10	1386-1396	expression	_	_	
8-11	1397-1399	of	_	_	
8-12	1400-1401	a	_	_	
8-13	1402-1413	recombinant	_	_	
8-14	1414-1428	polynucleotide	_	_	
8-15	1429-1437	encoding	_	_	
8-16	1438-1449	adiponectin	_	_	
8-17	1450-1452	or	_	_	
8-18	1453-1454	a	_	_	
8-19	1455-1466	polypeptide	_	_	
8-20	1467-1473	having	_	_	
8-21	1474-1477	the	_	_	
8-22	1478-1486	sequence	_	_	
8-23	1487-1489	of	_	_	
8-24	1490-1493	any	_	_	
8-25	1494-1496	of	_	_	
8-26	1497-1502	those	_	_	
8-27	1503-1510	animals	_	_	
8-28	1511-1512	(	_	_	
8-29	1512-1515	e.g	_	_	
8-30	1515-1516	.	_	_	
8-31	1516-1517	,	_	_	
8-32	1518-1523	human	_	_	
8-33	1523-1524	,	_	_	
8-34	1525-1530	mouse	_	_	
8-35	1530-1531	,	_	_	
8-36	1532-1535	etc	_	_	
8-37	1535-1536	.	_	_	
8-38	1536-1537	)	_	_	
8-39	1538-1547	described	_	_	
8-40	1548-1550	in	_	_	
8-41	1551-1554	FIG	_	_	
8-42	1554-1555	.	_	_	
8-43	1556-1557	5	_	_	
8-44	1558-1560	or	_	_	
8-45	1561-1562	a	_	_	
8-46	1563-1575	biologically	_	_	
8-47	1576-1582	active	_	_	
8-48	1583-1591	fragment	_	_	
8-49	1592-1594	or	_	_	
8-50	1595-1603	addition	_	_	
8-51	1604-1611	thereof	_	_	
8-52	1611-1612	,	_	_	
8-53	1613-1615	or	_	_	
8-54	1616-1621	other	_	_	
8-55	1622-1629	variant	_	_	
8-56	1630-1632	or	_	_	
8-57	1633-1640	agonist	_	_	
8-58	1641-1648	thereof	_	_	
8-59	1649-1651	in	_	_	
8-60	1652-1661	mammalian	_	_	
8-61	1662-1667	cells	_	_	
8-62	1667-1668	.	_	_	
8-63	1669-1670	[	_	_	
8-64	1670-1674	0543	_	_	
8-65	1674-1675	]	_	_	
8-66	1676-1678	In	_	_	
8-67	1679-1686	another	_	_	
8-68	1687-1697	embodiment	_	_	
8-69	1697-1698	,	_	_	
8-70	1699-1710	adiponectin	_	_	
8-71	1711-1712	(	_	_	
8-72	1712-1721	including	_	_	
8-73	1722-1730	mixtures	_	_	
8-74	1731-1733	of	_	_	
8-75	1734-1742	isoforms	_	_	
8-76	1743-1746	and	_	_	
8-77	1747-1760	glycoisoforms	_	_	
8-78	1760-1761	)	_	_	
8-79	1762-1765	can	_	_	
8-80	1766-1770	also	_	_	
8-81	1771-1773	be	_	_	
8-82	1774-1782	purified	_	_	
8-83	1783-1787	from	_	_	
8-84	1788-1790	an	_	_	
8-85	1791-1797	animal	_	_	
8-86	1798-1804	tissue	_	_	
8-87	1805-1809	such	_	_	
8-88	1810-1812	as	_	_	
8-89	1812-1813	,	_	_	
8-90	1814-1817	but	_	_	
8-91	1818-1821	not	_	_	
8-92	1822-1829	limited	_	_	
8-93	1830-1832	to	_	_	
8-94	1832-1833	,	_	_	
8-95	1834-1839	serum	_	_	
8-96	1840-1842	or	_	_	
8-97	1843-1853	adipocytes	_	_	
8-98	1853-1854	.	_	_	

#Text=Methods for purifying adiponectin from adipocytes are well-known in the art and further described in the Examples.
9-1	1855-1862	Methods	_	_	
9-2	1863-1866	for	_	_	
9-3	1867-1876	purifying	_	_	
9-4	1877-1888	adiponectin	_	_	
9-5	1889-1893	from	_	_	
9-6	1894-1904	adipocytes	_	_	
9-7	1905-1908	are	_	_	
9-8	1909-1919	well-known	_	_	
9-9	1920-1922	in	_	_	
9-10	1923-1926	the	_	_	
9-11	1927-1930	art	_	_	
9-12	1931-1934	and	_	_	
9-13	1935-1942	further	_	_	
9-14	1943-1952	described	_	_	
9-15	1953-1955	in	_	_	
9-16	1956-1959	the	_	_	
9-17	1960-1968	Examples	_	_	
9-18	1968-1969	.	_	_	

#Text=The animals from which the composition of glycosylated adiponectin can be obtained include but are not limited to humans, mice, rats, dogs, bovines, and non-human primates.
#Text=[0544] Adiponectin, obtained either recombinantly or from animal tissues, can be separated on the basis of molecular weight, pI, and/or the amount of glycosylation present within the adiponectin polypeptide by routine methods, e.g., electrophoresis or chromatography as disclosed in the Examples.
10-1	1970-1973	The	_	_	
10-2	1974-1981	animals	_	_	
10-3	1982-1986	from	_	_	
10-4	1987-1992	which	_	_	
10-5	1993-1996	the	_	_	
10-6	1997-2008	composition	_	_	
10-7	2009-2011	of	_	_	
10-8	2012-2024	glycosylated	_	_	
10-9	2025-2036	adiponectin	_	_	
10-10	2037-2040	can	_	_	
10-11	2041-2043	be	_	_	
10-12	2044-2052	obtained	_	_	
10-13	2053-2060	include	_	_	
10-14	2061-2064	but	_	_	
10-15	2065-2068	are	_	_	
10-16	2069-2072	not	_	_	
10-17	2073-2080	limited	_	_	
10-18	2081-2083	to	_	_	
10-19	2084-2090	humans	_	_	
10-20	2090-2091	,	_	_	
10-21	2092-2096	mice	_	_	
10-22	2096-2097	,	_	_	
10-23	2098-2102	rats	_	_	
10-24	2102-2103	,	_	_	
10-25	2104-2108	dogs	_	_	
10-26	2108-2109	,	_	_	
10-27	2110-2117	bovines	_	_	
10-28	2117-2118	,	_	_	
10-29	2119-2122	and	_	_	
10-30	2123-2132	non-human	_	_	
10-31	2133-2141	primates	_	_	
10-32	2141-2142	.	_	_	
10-33	2143-2144	[	_	_	
10-34	2144-2148	0544	_	_	
10-35	2148-2149	]	_	_	
10-36	2150-2161	Adiponectin	_	_	
10-37	2161-2162	,	_	_	
10-38	2163-2171	obtained	_	_	
10-39	2172-2178	either	_	_	
10-40	2179-2192	recombinantly	_	_	
10-41	2193-2195	or	_	_	
10-42	2196-2200	from	_	_	
10-43	2201-2207	animal	_	_	
10-44	2208-2215	tissues	_	_	
10-45	2215-2216	,	_	_	
10-46	2217-2220	can	_	_	
10-47	2221-2223	be	_	_	
10-48	2224-2233	separated	_	_	
10-49	2234-2236	on	_	_	
10-50	2237-2240	the	_	_	
10-51	2241-2246	basis	_	_	
10-52	2247-2249	of	_	_	
10-53	2250-2259	molecular	_	_	
10-54	2260-2266	weight	_	_	
10-55	2266-2267	,	_	_	
10-56	2268-2270	pI	_	_	
10-57	2270-2271	,	_	_	
10-58	2272-2275	and	_	_	
10-59	2275-2276	/	_	_	
10-60	2276-2278	or	_	_	
10-61	2279-2282	the	_	_	
10-62	2283-2289	amount	_	_	
10-63	2290-2292	of	_	_	
10-64	2293-2306	glycosylation	_	_	
10-65	2307-2314	present	_	_	
10-66	2315-2321	within	_	_	
10-67	2322-2325	the	_	_	
10-68	2326-2337	adiponectin	_	_	
10-69	2338-2349	polypeptide	_	_	
10-70	2350-2352	by	_	_	
10-71	2353-2360	routine	_	_	
10-72	2361-2368	methods	_	_	
10-73	2368-2369	,	_	_	
10-74	2370-2373	e.g	_	_	
10-75	2373-2374	.	_	_	
10-76	2374-2375	,	_	_	
10-77	2376-2391	electrophoresis	_	_	
10-78	2392-2394	or	_	_	
10-79	2395-2409	chromatography	_	_	
10-80	2410-2412	as	_	_	
10-81	2413-2422	disclosed	_	_	
10-82	2423-2425	in	_	_	
10-83	2426-2429	the	_	_	
10-84	2430-2438	Examples	_	_	
10-85	2438-2439	.	_	_	

#Text=In one aspect of the invention, adiponectin compositions containing specified isoforms or glycoisoforms of adiponectin, e.g., as described above, are prepared by differential purification.
11-1	2440-2442	In	_	_	
11-2	2443-2446	one	_	_	
11-3	2447-2453	aspect	_	_	
11-4	2454-2456	of	_	_	
11-5	2457-2460	the	_	_	
11-6	2461-2470	invention	_	_	
11-7	2470-2471	,	_	_	
11-8	2472-2483	adiponectin	_	_	
11-9	2484-2496	compositions	_	_	
11-10	2497-2507	containing	_	_	
11-11	2508-2517	specified	_	_	
11-12	2518-2526	isoforms	_	_	
11-13	2527-2529	or	_	_	
11-14	2530-2543	glycoisoforms	_	_	
11-15	2544-2546	of	_	_	
11-16	2547-2558	adiponectin	_	_	
11-17	2558-2559	,	_	_	
11-18	2560-2563	e.g	_	_	
11-19	2563-2564	.	_	_	
11-20	2564-2565	,	_	_	
11-21	2566-2568	as	_	_	
11-22	2569-2578	described	_	_	
11-23	2579-2584	above	_	_	
11-24	2584-2585	,	_	_	
11-25	2586-2589	are	_	_	
11-26	2590-2598	prepared	_	_	
11-27	2599-2601	by	_	_	
11-28	2602-2614	differential	*[1]	13-1[2_1]	
11-29	2615-2627	purification	*[1]	_	
11-30	2627-2628	.	_	_	

#Text=For example, according to a method of the invention, this involves obtaining a first composition containing at least two forms of adiponectin that differ in their degree or type of glycosylation and then separating the adiponectin forms based on the degree or tripe of glycosylation.
12-1	2629-2632	For	_	_	
12-2	2633-2640	example	_	_	
12-3	2640-2641	,	_	_	
12-4	2642-2651	according	_	_	
12-5	2652-2654	to	_	_	
12-6	2655-2656	a	_	_	
12-7	2657-2663	method	_	_	
12-8	2664-2666	of	_	_	
12-9	2667-2670	the	_	_	
12-10	2671-2680	invention	_	_	
12-11	2680-2681	,	_	_	
12-12	2682-2686	this	_	_	
12-13	2687-2695	involves	_	_	
12-14	2696-2705	obtaining	_	_	
12-15	2706-2707	a	_	_	
12-16	2708-2713	first	_	_	
12-17	2714-2725	composition	_	_	
12-18	2726-2736	containing	_	_	
12-19	2737-2739	at	_	_	
12-20	2740-2745	least	_	_	
12-21	2746-2749	two	_	_	
12-22	2750-2755	forms	_	_	
12-23	2756-2758	of	_	_	
12-24	2759-2770	adiponectin	_	_	
12-25	2771-2775	that	_	_	
12-26	2776-2782	differ	_	_	
12-27	2783-2785	in	_	_	
12-28	2786-2791	their	_	_	
12-29	2792-2798	degree	_	_	
12-30	2799-2801	or	_	_	
12-31	2802-2806	type	_	_	
12-32	2807-2809	of	_	_	
12-33	2810-2823	glycosylation	_	_	
12-34	2824-2827	and	_	_	
12-35	2828-2832	then	_	_	
12-36	2833-2843	separating	_	_	
12-37	2844-2847	the	_	_	
12-38	2848-2859	adiponectin	_	_	
12-39	2860-2865	forms	_	_	
12-40	2866-2871	based	_	_	
12-41	2872-2874	on	_	_	
12-42	2875-2878	the	_	_	
12-43	2879-2885	degree	_	_	
12-44	2886-2888	or	_	_	
12-45	2889-2894	tripe	_	_	
12-46	2895-2897	of	_	_	
12-47	2898-2911	glycosylation	_	_	
12-48	2911-2912	.	_	_	

#Text=This method produces a second composition that differs from the first composition in the adiponectin profile.
#Text=[0545] Glycosylated adiponectin polypeptide can be separated from other polypeptides by several methods known in the protein purification art.
13-1	2913-2917	This	*[2]	_	
13-2	2918-2924	method	*[2]	_	
13-3	2925-2933	produces	_	_	
13-4	2934-2935	a	_	_	
13-5	2936-2942	second	_	_	
13-6	2943-2954	composition	_	_	
13-7	2955-2959	that	_	_	
13-8	2960-2967	differs	_	_	
13-9	2968-2972	from	_	_	
13-10	2973-2976	the	_	_	
13-11	2977-2982	first	_	_	
13-12	2983-2994	composition	_	_	
13-13	2995-2997	in	_	_	
13-14	2998-3001	the	_	_	
13-15	3002-3013	adiponectin	_	_	
13-16	3014-3021	profile	_	_	
13-17	3021-3022	.	_	_	
13-18	3023-3024	[	_	_	
13-19	3024-3028	0545	_	_	
13-20	3028-3029	]	_	_	
13-21	3030-3042	Glycosylated	_	_	
13-22	3043-3054	adiponectin	_	_	
13-23	3055-3066	polypeptide	_	_	
13-24	3067-3070	can	_	_	
13-25	3071-3073	be	_	_	
13-26	3074-3083	separated	_	_	
13-27	3084-3088	from	_	_	
13-28	3089-3094	other	_	_	
13-29	3095-3107	polypeptides	_	_	
13-30	3108-3110	by	_	_	
13-31	3111-3118	several	_	_	
13-32	3119-3126	methods	_	_	
13-33	3127-3132	known	_	_	
13-34	3133-3135	in	_	_	
13-35	3136-3139	the	_	_	
13-36	3140-3147	protein	_	_	
13-37	3148-3160	purification	_	_	
13-38	3161-3164	art	_	_	
13-39	3164-3165	.	_	_	

#Text=In one embodiment, the separation is effected by two-dimensional electrophoresis and subsequent excision and elution of the protein from the gel.
14-1	3166-3168	In	_	_	
14-2	3169-3172	one	_	_	
14-3	3173-3183	embodiment	_	_	
14-4	3183-3184	,	_	_	
14-5	3185-3188	the	_	_	
14-6	3189-3199	separation	_	_	
14-7	3200-3202	is	_	_	
14-8	3203-3211	effected	_	_	
14-9	3212-3214	by	_	_	
14-10	3215-3230	two-dimensional	_	_	
14-11	3231-3246	electrophoresis	_	_	
14-12	3247-3250	and	_	_	
14-13	3251-3261	subsequent	_	_	
14-14	3262-3270	excision	_	_	
14-15	3271-3274	and	_	_	
14-16	3275-3282	elution	_	_	
14-17	3283-3285	of	_	_	
14-18	3286-3289	the	_	_	
14-19	3290-3297	protein	_	_	
14-20	3298-3302	from	_	_	
14-21	3303-3306	the	_	_	
14-22	3307-3310	gel	_	_	
14-23	3310-3311	.	_	_	

#Text=In another embodiment, the separation is effected by using an affinity column which selects on the basis of electrical charge.
15-1	3312-3314	In	_	_	
15-2	3315-3322	another	_	_	
15-3	3323-3333	embodiment	_	_	
15-4	3333-3334	,	_	_	
15-5	3335-3338	the	_	_	
15-6	3339-3349	separation	_	_	
15-7	3350-3352	is	_	_	
15-8	3353-3361	effected	_	_	
15-9	3362-3364	by	_	_	
15-10	3365-3370	using	_	_	
15-11	3371-3373	an	_	_	
15-12	3374-3382	affinity	_	_	
15-13	3383-3389	column	_	_	
15-14	3390-3395	which	_	_	
15-15	3396-3403	selects	_	_	
15-16	3404-3406	on	_	_	
15-17	3407-3410	the	_	_	
15-18	3411-3416	basis	_	_	
15-19	3417-3419	of	_	_	
15-20	3420-3430	electrical	_	_	
15-21	3431-3437	charge	_	_	
15-22	3437-3438	.	_	_	

#Text=In another embodiment, the separation is effected by using an affinity column loaded with lectins.
16-1	3439-3441	In	_	_	
16-2	3442-3449	another	_	_	
16-3	3450-3460	embodiment	_	_	
16-4	3460-3461	,	_	_	
16-5	3462-3465	the	_	_	
16-6	3466-3476	separation	_	_	
16-7	3477-3479	is	_	_	
16-8	3480-3488	effected	_	_	
16-9	3489-3491	by	_	_	
16-10	3492-3497	using	_	_	
16-11	3498-3500	an	_	_	
16-12	3501-3509	affinity	_	_	
16-13	3510-3516	column	_	_	
16-14	3517-3523	loaded	_	_	
16-15	3524-3528	with	_	_	
16-16	3529-3536	lectins	_	_	
16-17	3536-3537	.	_	_	

#Text=In other embodiments, alternate protein purification methods are used, e.g., immunoaffinity column, size-exclusion column, lectin affinity, hydrophobic interaction, reversed phase, anion and cation exchange chromatography, and the like (see, generally, R.
17-1	3538-3540	In	_	_	
17-2	3541-3546	other	_	_	
17-3	3547-3558	embodiments	_	_	
17-4	3558-3559	,	_	_	
17-5	3560-3569	alternate	_	_	
17-6	3570-3577	protein	_	_	
17-7	3578-3590	purification	_	_	
17-8	3591-3598	methods	_	_	
17-9	3599-3602	are	_	_	
17-10	3603-3607	used	_	_	
17-11	3607-3608	,	_	_	
17-12	3609-3612	e.g	_	_	
17-13	3612-3613	.	_	_	
17-14	3613-3614	,	_	_	
17-15	3615-3629	immunoaffinity	_	_	
17-16	3630-3636	column	_	_	
17-17	3636-3637	,	_	_	
17-18	3638-3652	size-exclusion	_	_	
17-19	3653-3659	column	_	_	
17-20	3659-3660	,	_	_	
17-21	3661-3667	lectin	_	_	
17-22	3668-3676	affinity	_	_	
17-23	3676-3677	,	_	_	
17-24	3678-3689	hydrophobic	_	_	
17-25	3690-3701	interaction	_	_	
17-26	3701-3702	,	_	_	
17-27	3703-3711	reversed	_	_	
17-28	3712-3717	phase	_	_	
17-29	3717-3718	,	_	_	
17-30	3719-3724	anion	_	_	
17-31	3725-3728	and	_	_	
17-32	3729-3735	cation	_	_	
17-33	3736-3744	exchange	_	_	
17-34	3745-3759	chromatography	_	_	
17-35	3759-3760	,	_	_	
17-36	3761-3764	and	_	_	
17-37	3765-3768	the	_	_	
17-38	3769-3773	like	_	_	
17-39	3774-3775	(	_	_	
17-40	3775-3778	see	_	_	
17-41	3778-3779	,	_	_	
17-42	3780-3789	generally	_	_	
17-43	3789-3790	,	_	_	
17-44	3791-3792	R	_	_	
17-45	3792-3793	.	_	_	

#Text=Scopes, Protein Purification, Springer-Verlag, N.Y. (1982) and Deutscher, Methods in Enzymology Vol. 182: Guide to Protein Purification, Academic Press, Inc.
18-1	3794-3800	Scopes	_	_	
18-2	3800-3801	,	_	_	
18-3	3802-3809	Protein	_	_	
18-4	3810-3822	Purification	_	_	
18-5	3822-3823	,	_	_	
18-6	3824-3839	Springer-Verlag	_	_	
18-7	3839-3840	,	_	_	
18-8	3841-3844	N.Y	_	_	
18-9	3844-3845	.	_	_	
18-10	3846-3847	(	_	_	
18-11	3847-3851	1982	_	_	
18-12	3851-3852	)	_	_	
18-13	3853-3856	and	_	_	
18-14	3857-3866	Deutscher	_	_	
18-15	3866-3867	,	_	_	
18-16	3868-3875	Methods	_	_	
18-17	3876-3878	in	_	_	
18-18	3879-3889	Enzymology	_	_	
18-19	3890-3893	Vol	_	_	
18-20	3893-3894	.	_	_	
18-21	3895-3898	182	_	_	
18-22	3898-3899	:	_	_	
18-23	3900-3905	Guide	_	_	
18-24	3906-3908	to	_	_	
18-25	3909-3916	Protein	_	_	
18-26	3917-3929	Purification	_	_	
18-27	3929-3930	,	_	_	
18-28	3931-3939	Academic	_	_	
18-29	3940-3945	Press	_	_	
18-30	3945-3946	,	_	_	
18-31	3947-3950	Inc	_	_	
18-32	3950-3951	.	_	_	

#Text=N.Y. (1990)).
#Text=[0546] In one embodiment, compositions containing predominantly glycosylated adiponectin polypeptides are obtained by using a lectin column, for example, a concanavalin A or wheat germ agglutinin column, to bind glycosylated adiponectin polypeptides.
19-1	3952-3955	N.Y	_	_	
19-2	3955-3956	.	_	_	
19-3	3957-3958	(	_	_	
19-4	3958-3962	1990	_	_	
19-5	3962-3963	)	_	_	
19-6	3963-3964	)	_	_	
19-7	3964-3965	.	_	_	
19-8	3966-3967	[	_	_	
19-9	3967-3971	0546	_	_	
19-10	3971-3972	]	_	_	
19-11	3973-3975	In	_	_	
19-12	3976-3979	one	_	_	
19-13	3980-3990	embodiment	_	_	
19-14	3990-3991	,	_	_	
19-15	3992-4004	compositions	_	_	
19-16	4005-4015	containing	_	_	
19-17	4016-4029	predominantly	_	_	
19-18	4030-4042	glycosylated	_	_	
19-19	4043-4054	adiponectin	_	_	
19-20	4055-4067	polypeptides	_	_	
19-21	4068-4071	are	_	_	
19-22	4072-4080	obtained	_	_	
19-23	4081-4083	by	_	_	
19-24	4084-4089	using	_	_	
19-25	4090-4091	a	_	_	
19-26	4092-4098	lectin	_	_	
19-27	4099-4105	column	_	_	
19-28	4105-4106	,	_	_	
19-29	4107-4110	for	_	_	
19-30	4111-4118	example	_	_	
19-31	4118-4119	,	_	_	
19-32	4120-4121	a	_	_	
19-33	4122-4134	concanavalin	_	_	
19-34	4135-4136	A	_	_	
19-35	4137-4139	or	_	_	
19-36	4140-4145	wheat	_	_	
19-37	4146-4150	germ	_	_	
19-38	4151-4161	agglutinin	_	_	
19-39	4162-4168	column	_	_	
19-40	4168-4169	,	_	_	
19-41	4170-4172	to	_	_	
19-42	4173-4177	bind	_	_	
19-43	4178-4190	glycosylated	_	_	
19-44	4191-4202	adiponectin	_	_	
19-45	4203-4215	polypeptides	_	_	
19-46	4215-4216	.	_	_	

#Text=Non-glycosylated adiponectin will not bind to the column and thus, will flow through the column.
20-1	4217-4233	Non-glycosylated	_	_	
20-2	4234-4245	adiponectin	_	_	
20-3	4246-4250	will	_	_	
20-4	4251-4254	not	_	_	
20-5	4255-4259	bind	_	_	
20-6	4260-4262	to	_	_	
20-7	4263-4266	the	_	_	
20-8	4267-4273	column	_	_	
20-9	4274-4277	and	_	_	
20-10	4278-4282	thus	_	_	
20-11	4282-4283	,	_	_	
20-12	4284-4288	will	_	_	
20-13	4289-4293	flow	_	_	
20-14	4294-4301	through	_	_	
20-15	4302-4305	the	_	_	
20-16	4306-4312	column	_	_	
20-17	4312-4313	.	_	_	

#Text=The glycosylated adiponectin polypeptides are then eluted from the column to obtain a composition containing predominantly glycosylated adiponectin polypeptides.
21-1	4314-4317	The	_	_	
21-2	4318-4330	glycosylated	_	_	
21-3	4331-4342	adiponectin	_	_	
21-4	4343-4355	polypeptides	_	_	
21-5	4356-4359	are	_	_	
21-6	4360-4364	then	_	_	
21-7	4365-4371	eluted	_	_	
21-8	4372-4376	from	_	_	
21-9	4377-4380	the	_	_	
21-10	4381-4387	column	_	_	
21-11	4388-4390	to	_	_	
21-12	4391-4397	obtain	_	_	
21-13	4398-4399	a	_	_	
21-14	4400-4411	composition	_	_	
21-15	4412-4422	containing	_	_	
21-16	4423-4436	predominantly	_	_	
21-17	4437-4449	glycosylated	_	_	
21-18	4450-4461	adiponectin	_	_	
21-19	4462-4474	polypeptides	_	_	
21-20	4474-4475	.	_	_	
